Thyrocare Technologies Limited Approves ₹141.40 Crore NHL Sale

Thyrocare Technologies Limited has approved the proposed sale of its entire stake in Nueclear Healthcare Limited to Trovera Healthcare Private Limited for approximately ₹141.40 crore. The deal would separate Thyrocare from its radiology and diagnostic imaging subsidiary, with ₹81.90 crore payable in cash and ₹59.50 crore payable through Trovera preference shares.

What has Thyrocare approved for Nueclear Healthcare?

Thyrocare Technologies Limited approved the proposed divestment of its entire 100% holding in Nueclear Healthcare Limited, its material wholly owned subsidiary, at a board meeting on September 21, 2026. Nueclear Healthcare operates Thyrocare's radiology and diagnostic imaging business.

The proposed buyer is Trovera Healthcare Private Limited. The transaction value is approximately ₹141.40 crore, although the final cash amount is subject to working-capital adjustments. The company said the sale remains subject to shareholder approval and other applicable approvals.

The board meeting also approved Thyrocare's unaudited standalone and consolidated financial results for the quarter ended September 30, 2026, along with the limited review reports. No quarterly financial figures were included in the information provided on the proposed divestment.

How is the ₹141.40 crore consideration structured?

The consideration comprises approximately ₹81.90 crore in cash and 42,500 compulsorily convertible preference shares, or CCPS, of Trovera valued at ₹59.50 crore. The combined value of these two components is approximately ₹141.40 crore.

Trovera's CCPS are stated to be issued at ₹14,000 each, including a premium of ₹13,990 per share. They are compulsorily convertible into Trovera equity shares on a 1:1 basis. Based on the disclosed terms, the shares would represent about 4.5% of Trovera's share capital.

The proposed share sale covers 1,11,11,000 equity shares of Nueclear Healthcare, representing its full issued and paid-up equity capital. Thyrocare's disclosures describe the transaction as a cash-and-equity arrangement rather than a wholly cash-funded sale.

Why is Thyrocare selling its radiology business?

The proposed sale would allow Thyrocare to exit the radiology segment and focus on its core pathology business. Nueclear Healthcare has been identified in the disclosures as the entity operating the group's radiology and diagnostic imaging activities.

The transaction comes as API Holdings, the parent of Thyrocare, continues a broader business restructuring. The available disclosures do not provide a separate financial contribution from Nueclear Healthcare or quantify how the sale may affect Thyrocare's future revenue, profit, or operating margins.

Thyrocare intends to retain certain operating premises used for its laboratory activities. Alongside the proposed stake sale, it plans to purchase immovable properties, including land and buildings in Gurugram and Hyderabad, from Nueclear Healthcare for approximately ₹20.58 crore. This property purchase is distinct from the ₹141.40 crore consideration for the equity stake.

What approvals and conditions remain before closing?

The sale cannot be completed until Thyrocare shareholders approve the proposal and the parties satisfy applicable regulatory, contractual, and other conditions precedent. The available information also indicates that the proposed share purchase agreement was yet to be executed at the time of the announcement.

The target board, regulatory board or committee, and target shareholder approvals were identified among the required steps in the transaction information. This means the board approval is an important step but does not by itself complete the ownership transfer.

Thyrocare expects the transaction to close on or before November 30, 2026, subject to these conditions. The stated timetable gives investors a defined near-term milestone, while the working-capital adjustment means the final cash consideration may differ from the approximate ₹81.90 crore disclosed.

How does the deal affect Thyrocare and its investors?

For Thyrocare, the proposed transaction separates the radiology and imaging business from the pathology operations it intends to retain. The company would receive a mix of immediate cash and an equity-linked investment in Trovera through CCPS, instead of receiving the full consideration in cash.

The CCPS structure gives Thyrocare a future equity interest in Trovera once the instruments convert on the stated 1:1 basis. However, the value ultimately realised from that component will depend on the terms of the conversion and Trovera's equity value after conversion. No public-market price comparison is available because Trovera is a private company.

For shareholders, the principal disclosed issues are whether the required approvals are obtained, whether the agreement is executed, and whether the transaction closes within the planned timeline. The announcement does not disclose a share-price movement, earnings guidance, or a quantified financial impact from the divestment.

Conclusion

Thyrocare has approved a proposed ₹141.40 crore sale of its full holding in Nueclear Healthcare to Trovera, marking a planned exit from radiology and diagnostic imaging. The consideration combines approximately ₹81.90 crore of cash with ₹59.50 crore of Trovera CCPS, while Thyrocare plans to retain laboratory premises in Gurugram and Hyderabad through a separate property purchase.

The next developments to watch are shareholder approval, execution of the proposed share purchase agreement, satisfaction of the stated conditions precedent, and the targeted completion on or before November 30, 2026. The final cash amount will also depend on the working-capital adjustment specified in the transaction terms.